-
Barron's On: Pharma's Big Hope
Sunday, March 3, 2019 - 10:47am | 465This weekend's Barron's cover story looks at why pharmaceutical giants are making big bets on gene therapy. See which companies already have been snapped up and which ones may be the next targets. Other notable articles offer a look at the implications of the tax law and a retirement guide...
-
9 Notable Biotechs Presenting At This Year's ASH Meeting
Monday, November 6, 2017 - 4:31pm | 1142One of the biggest biotech conferences of the year is around the corner. The 59th annual meeting of the American Society of Hematology, or ASH, is Dec. 9-12 in Atlanta. It's likely to serve as a make-or-break catalyst for many companies researching blood-related diseases and disorders. About 3,...
-
Barron's Picks And Pans: Amazon, Novartis, Tesla And More
Sunday, May 7, 2017 - 1:06pm | 642This weekend's Barron's takes a look at why the king of e-commerce must avoid becoming too profitable. Other featured articles offer the prospects for retail stocks that benefit from woes in the sector and a Swiss drug giant with an underappreciated pipeline. The outlook for the...
-
Cowen Downgrades Novartis, Strengths 'Now Balance Its Risks'
Wednesday, April 5, 2017 - 11:36am | 347Steve Scala of Cowen downgraded shares of Novartis AG (ADR) (NYSE: NVS) from Outperform to Market Perform with a price target lowered to $77 from $87 as the company's strengths "now balance its risks." According to Scala's estimates, Novartis' earnings per share growth from...
-
Short Interest In Conatus Pharmaceuticals Surges
Friday, January 13, 2017 - 6:45am | 330Short sellers loaded up on this biotech stock in the most recent period. The company announced a license agreement back in December. The share price rose to a new high between the most recent settlement dates. After Conatus Pharmaceuticals Inc (NASDAQ: CNAT) announced a new licensing...
-
Barron's Best Income Ideas For 2017
Monday, January 2, 2017 - 5:26pm | 675The cover story in this weekend's Barron's examines where to go and not go for yield in 2017. It's Barron's fifth annual assessment of income-producing investments in 10 sectors. Other featured articles offer Barron's latest picks and pans, as well as experts on...
-
Barron's Picks And Pans: Trump Stocks, Hillary Stocks, Safe European Yields And More
Sunday, August 14, 2016 - 9:12am | 673This weekend's Barron's anticipates which stocks will be the winners and which the losers if each presidential candidate wins. Five European stocks with generous but safe yields are also examined. Other featured articles ponder the prospects for an operator of seniors residences...
-
Regeneron Is 'One Of The Stronger Growers In Biotech'
Wednesday, June 29, 2016 - 2:04pm | 416Bernstein has initiated coverage of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) with an Outperform rating and $400 price target, citing a "good entry point for one of stronger growers in biotech." "Regeneron is a growth-phase biopharma with one large successful first product (Eylea) and two...
-
Novartis' CEO Says Company Open To Selling Its $14 Billion Stake In Roche 'If The Opportunity Were Right'
Wednesday, May 25, 2016 - 8:41am | 207Switzerland-based Novartis AG (ADR) (NYSE: NVS) owns a roughly $14 billion stake in rival Roche Holding Ltd. (ADR) (OTC: RHHBY) and is actively shopping for buyers to acquire its stake. According to Reuters, Novartis has been working with bankers to explore the sale of its stake in Roche and would...
-
Novartis Announces The Establishment Of FortiHFy, But What Is It?
Thursday, May 19, 2016 - 9:04am | 303Novartis AG (ADR) (NYSE: NVS) announced on Thursday the establishment of FortiHFy, short for Fortifying Heart Failure clinical evidence and patient quality of life. FortiHFy is an umbrella clinical program that consists of over 40 active or planned trials. The global clinical program will result in...
-
Bayer's Latest Stage 2 Trial Could Be A Boon For Shares
Monday, August 31, 2015 - 2:14pm | 404Bayer AG (ADR) (OTC: BAYRY) recently finished a mid-stage trial for a heart failure drug, finerenone, which showed a "striking" decline in deaths. Now, a Reuters article informed that the company will move into a final-stage trial before the end of the year. It should be noted, however...
-
Repeat Performance In Aveo Pharmaceuticals After Spike In Price
Monday, August 17, 2015 - 12:34pm | 228Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show. Aveo Pharmaceuticals, Inc. (NASDAQ: AVEO) shares were trading higher by $0.61 (49 percent) at $1.78 in Monday's session. The issue has retreated over $1.20 from its pre-market high ($2.97) and $0...
-
Markets Continue To Rally As The Dow Closes Above 17,000
Tuesday, October 28, 2014 - 3:44pm | 1552U.S. stocks continued to charge forward as the Dow closed above the 17,000 mark as consumer confidence rose more than expected in October. The Federal Reserve gathered Tuesday and will release a statement on Wednesday at 2:00 p.m. ET. It is not a foregone conclusion that the Federal Reserve...
-
5 New Medical Technologies For Diabetics
Friday, July 18, 2014 - 12:10pm | 788News of the recent partnership between European drugmaker Novartis (NYSE: NVS) and Google (NASDAQ: GOOG) (NASDAQ: GOOGL) to develop a contact lens designed to monitor blood sugar levels in diabetics has drawn attention to several other new diabetes treatment developments. Information Week...
-
Novartis Joins Google To Develop Contacts For Diabetics
Friday, July 18, 2014 - 8:59am | 606Development of devices and mobile applications in the health care sector has exploded of late. Now, according to The New York Times, drugmaker Novartis (NYSE: NVS) is collaborating with Google (NASDAQ: GOOG) (NASDAQ: GOOGL) to develop a smart contact lens that would constantly monitor the blood...